March 13, 2017 / 12:29 PM / 4 months ago

BRIEF-Daiichi Sankyo announces new analyses

1 Min Read

March 13 (Reuters) - Daiichi Sankyo Co Ltd:

* Daiichi Sankyo Inc announces new analyses of once-daily savaysa (edoxaban) in patients with non-valvular atrial fibrillation to be presented at the acc 66th annual scientific session

* Daiichi Sankyo Co Ltd says edoxaban was found to be superior for principal safety endpoint of major bleeding in comparison to warfarin Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below